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lates, based on the meropenem susceptibility test result and
the use of meropenem disks supplemented with APB, cloxa-
cillin or DPA. These tests will enable routine laboratories to
identify, with high conﬁdence levels, those P. aeruginosa iso-
lates suspected of producing either KPC or MBL carbapene-
mases.
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Abstract
Fifty-six isolates of serotype 1 were identiﬁed during a 20-year
prospective study (1989–2008), including all children with cul-
ture-proven invasive pneumococcal disease (IPD) admitted to a
children’s hospital in Barcelona. Forty-eight of them (85.7%)
were in children aged >2 years. Complicated pneumonia
(n = 28) and non-complicated pneumonia (n = 20) were the
main clinical presentations. The frequency of serotype 1 IPD
increased from 1999–2003 to 2004–2008: 1.2 to 4.4 episodes/
100 000 children (p <0.001). The ST306 clone were identiﬁed in
70.4% of isolates. As IPD caused by serotype 1 is mainly
detected in older children, a vaccination programme for children
>2 years should be considered.
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Invasive pneumococcal disease (IPD) is associated with high
rates of morbidity and mortality in children. Serotype 1 is
one of the most prevalent invasive serotypes of Streptococcus
pneumoniae. In recent years, several studies have found an
increase in IPD caused by serotype 1 in different countries
[1–5].
In this study, we analysed changes in the epidemiology of
serotype 1 among children in Barcelona, and determined the
clonal composition of invasive strains of serotype 1.
We carried out a 20-year prospective study that included
all children and adolescents aged <18 years with IPD who
were admitted to Sant Joan de De´u Hospital.
This is a 345-bed children’s teaching hospital located in
Barcelona that was responsible for 18.5% of all paediatric
hospitalizations in Catalonia, Spain in1999–2003 and 18.3% in
2004–2008. A detailed description of the methodology used
in this study has been reported elsewhere [6].
IPD was deﬁned as the presence of clinical ﬁndings of
infection together with isolation of S. pneumoniae in a blood
sample, cerebrospinal ﬂuid sample, or any other sterile ﬂuid
sample. Pneumococcal strains were serotyped by the Quel-
lung reaction, and clonal analysis was performed by multilo-
cus sequence typing (MLST).
For statistical analysis, we used the chi-square test or Fish-
er’s exact test, when appropriate, to compare proportions,
and Student’s t-test to compare means. Rates of IPD (epi-
sodes/100 000 population) were calculated from the annual
estimates of the paediatric population obtained from the
Department of Statistics in Catalonia [7].
A total of 347 episodes of IPD were identiﬁed. Fifty-six
of 344 episodes (16.3%) with the serotype available were
caused by serotype 1. According to age group, eight
episodes (14.3%) caused by serotype 1 were in children
aged <2 years, 19 episodes (33.9%) were in children aged
2–4 years, and 29 episodes (51.8%) were in children and
adolescents aged 5–17 years. Table 1 shows the characteris-
tics of patients with IPD caused by serotype 1 vs. other
serotypes.
On comparison of the proportion of serotype 1 with
respect to the total episodes of IPD, there was a statistically
signiﬁcant increase in serotype 1 throughout the study per-
iod: one of 51 episodes (2%) in 1989–1993; ﬁve of 58 epi-
sodes (8.6%) in 1994–1998; 11 of 74 episodes (14.9%) in
1999–2003; and 39 of 164 episodes (23.8%) in 2004–2008
(chi-square test for trend, p <0.001).
Fig. 1 shows the increase in incidence of IPD among chil-
dren throughout the study by age group. In addition, a statis-
tically signiﬁcant increase was observed on comparison of
the rates of serotype 1 per 1000 hospital admissions
between 1999–2003 and 2004–2008 (13 vs. 45.1 per 1000
admissions; Fisher’s-exact test, p <0.001) and comparison of
the rates of serotype 1 per 1000 blood cultures between the
two periods (12.8 vs. 79.2 per 1000 blood cultures; Fisher’s-
exact test, p <0.001).
According to the meningeal breakpoints of the CLSI [8], all
serotype 1 isolates were susceptible to penicillin and cefotax-
ime during the study period, but three strains (7.7%) detected
in 2004–2008 were resistant to erythromycin, and two (5.1%)
were also resistant to tetracycline and chloramphenicol.
Molecular analysis by MLST was performed in 55 of 56
(98.2%) serotype 1 isolates. Overall, there were ﬁve different
sequence types (STs) expressing serotype 1, including three
PMEN clones: ST306 (Sweden 1-28) in 39 isolates (71%),
ST304 (Sweden 1-40) in 11 isolates (20%), and ST217 (Swe-
den 1-27) in one isolate (1.8%). In addition, ST228, which is a
double-locus variant of Sweden 1-28, was detected in three
isolates (5.5%), and a new MLST proﬁle, ST2376, which is a
single-locus variant of Sweden 1-28, was detected in one iso-
late. Serotype 1 was detected for the ﬁrst time in 1994–
1998, and the ﬁrst STs detected were ST304 and ST228. All
ST306 isolates were detected after January 2000.
Some studies have suggested that certain surface or subsur-
face proteins of pneumococci may contribute signiﬁcantly to
the pathogenesis and virulence of some strains [9]. One
recently identiﬁed pneumococcal virulence determinant is the
pneumococcal serine-rich repeat protein (PsrP). Animal models
TABLE 1. Clinical manifestations of invasive pneumoccocal
disease (IPD) in children
Episodes (%),
serotype 1
(n = 56)
Episodes (%),
other serotypes
(n = 288) p-value
Age (months),
mean (±SD)
62.3 (42.0) 34.5 (39.2) p <0.001d
Sex
Female 27 (48.2) 115 (39.9) NS; p 0.44e
Male 29 (51.8) 173 (60.1)
PCV7 vaccinationa 5 (9.4) 25 (9.4) NS; p 0.78e
Clinical manifestations
of IPDb
Meningitis 1 (1.8) 70 (24.5) p <0.001e
Pneumonia (overall) 48 (85.7) 77 (26.9)
With empyema 28 40
Without empyema 20 37
Bacteraemia/sepsis 5 (8.9) 100 (34.9)
Appendicitis 2 (3.6) 9 (3.1)
Arthritis 0 28 (9.8)
Others 0 2 (0.7)
PICU admissionc 3 (5.3) 72 (27.6) p <0.001f
Mortality 0 13 (4.5) NS; p 0.1f
NS, not signiﬁcant; PCV7, heptavalent pneumococcal conjugate vaccine; PICU,
paediatric intensive care unit; SD, standard deviation.
aPCV7 vaccination status with was available in 319 patients (53 with serotype 1
and 266 with other serotypes).
bClinical manifestations of IPD were known in 342 patients (56 with serotype 1
and 286 with other serotypes).
cPICU admission status was available in 316 patients (56 with serotype 1 and
260 with other serotypes).
For statistical analysis, we used the chi-square test or Fisher’s exact test, when
appropriate, to compare proportions, and Student’s t-test to compare means:
dStudent’s t-test, echi-square test, fFisher’s exact test.
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have shown that PsrP mediates attachment to lung cells
[10,11]. In addition, we recently reported that PsrP is highly
prevalent in children with pneumonia and is strongly associated
with clonal type. In that study, PsrP was detected in all ST306
isolates studied (n = 88) [12]. Therefore, the introduction of
ST306 in our geographical area was associated with the intro-
duction of this virulence factor that could be related, in part, to
an increased ability of pneumococci to cause pneumonia.
Overall, younger children are a higher risk for IPD, owing
to the high rate of pneumococcal nasopharyngeal coloniza-
tion. However, serotype 1 is rarely found in the nasophar-
ynx, and it is a serotype with a low rate of colonization [13].
Nevertheless, in our series, the incidence of serotype 1 was
signiﬁcantly higher in older children than in younger children
(<2 years). This observation has also been reported by other
authors [14]. The low prevalence of serotype 1 in carriers
could also be an explanation for the low rate of antibiotic
resistance and the relative stability of clonal composition.
We have detected ﬁve different STs, which conﬁrms the high
homogeneity of this serotype described by other authors
[13] in comparison with the high diversity of other sero-
types, such as serotype 19A [15].
The presence of some clones in a speciﬁc geographical area
depends on several factors, such as the characteristics of the
people and social factors in that community and/or the viru-
lence of the clonal types [16]. Other authors have reported
that ST306 is a predominant clone in continental Europe
[5,17,18], whereas other STs, such as ST217, are more com-
mon in North America, England, Canada, and Gambia [14,19].
In conclusion, our study shows an increase in IPD caused by
serotype 1 among children in Barcelona. Implementation of the
new conjugate vaccines that include serotype 1 is urgently
needed to reduce the burden of IPD. As IPD caused by sero-
type 1 is mainly detected in older children, vaccination pro-
grammes for children aged >2 years should also be considered.
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FIG. 1. Incidence of invasive pneumococcal disease (IPD) among
children throughout the study period by age group. On comparison
of the pre-vaccine period, the early heptavalent pneumococcal conju-
gate vaccine (PCV7) period (1999–2003) and the late PCV7 period
(2004–2008), there was no statistically signiﬁcant increase in sero-
type 1 in children aged <2 years (1 vs. 3.5 per 100 000 population;
Fisher’s exact test, p 0.1), a statistically signiﬁcant increase in sero-
type 1 was observed in children aged 2–4 years (1.5 vs. 7.5 per
100 000 population; Fisher’s exact test, p 0.010), and there was a
trend for an increase in children and adolescents aged 5–17 years
(1.2 vs. 2.6 per 100 000 population; Fisher’s exact test, p 0.050).
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Outbreak of KPC-3-producing, and
colistin-resistant, Klebsiella pneumoniae
infections in two Sicilian hospitals
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Abstract
We report the ﬁrst outbreak caused by colistin-resistant Klebsiella
pneumoniae producing KPC-3 carbapenamase in two Italian
hospitals. This spread occurred in 1 month, and was caused by
eight colistin-resistant and carbapenem-resistant Klebsiella
pneumoniae isolates from eight patients. A further three isolates
were obtained from the intestinal tract and pharyngeal colonization.
All isolates were multidrug-resistant (MDR), including being resistant
to colistin, but they were susceptible to gentamicin and tigecycline.
PCR detection showed that all isolates harboured the blaKPC-3 gene
associated with blaSHV-11, blaTEM-1 and blaOXA-9. All K. pneumoniae
isolates, genotyped by pulsed-ﬁeld gel electrophoresis and
multilocus sequence typing, belonged to the same sequence type
(ST)258 clone. From our data and a review of the international
literature, K. pneumoniae ST258 seems to be the most widespread
genetic background for KPC dissemination in Europe.
Keywords: Colistin resistance, colonization, Klebsiella pneumo-
niae, KPC-3, ST258
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